Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.60 |
| ▸ | RPTOR | Q8N122 | 12/20 | 0.60 |
| ▸ | MLST8 | Q9BVC4 | 12/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29522243 | 1.00 | MTOR (0.60) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29521651 | 0.86 | MTOR (0.73) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL136218 | 0.86 | MTOR (0.73) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL138583 | 0.85 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522133 | 0.85 | MTOR (0.57) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL29522428 | 0.84 | MTOR (0.62) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL138998 | 0.84 | MTOR (0.62) | MTORRPTORMLST8PIK3CA | |
| SCHEMBL29521963 | 0.78 | MTOR (0.76) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138973 | 0.78 | MTOR (0.76) | MTORRPTORMLST8PIK3CACSF1R | |
| SCHEMBL138609 | 0.77 | MTOR (0.53) | MTORRPTORMLST8PIK3CACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369241-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | CELGENE CORP (US) | 2018-12-27 | — | — | US | claimed |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2017-04-06 | — | — | US | claimed |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2017-02-02 | — | — | US | claimed |
| EP-2493472-B1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARM LLC (US) | 2016-12-07 | — | — | EP | claimed |
| US-9415049-B2 | Heteroaryl compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-16 | — | — | US | claimed |
| EP-2908814-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | claimed |
| EP-2909627-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | claimed |
| US-9079900-B2 | Methods of synthesis and purification of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2015-07-14 | — | — | US | claimed |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-25 | — | — | US | claimed |
| WO-2014062878-A9 | TREATMENT OF PROSTATE CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-18 | — | — | WO | claimed |
| WO-2014062878-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-04-24 | — | — | WO | claimed |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | US | claimed |
| EP-2598885-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2013-06-05 | — | — | EP | claimed |
| US-8110578-B2 | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-07 | — | — | US | claimed |
| WO-2012016113-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | SIGNAL PHARMACEUTICALS, LLC | 2012-02-02 | — | — | US | claimed |
| EP-2358718-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | Signal Pharmaceuticals, LLC (US) | 2011-08-24 | — | — | EP | claimed |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | claimed |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC | 2010-08-26 | — | — | US | claimed |
| WO-2010062571-A1 | MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY | SIGNAL PHARMACEUTICALS, LLC (US) | 2010-06-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369241-A1 | TREATMENT OF CANCER WITH DNAPK INHIBITORS | DKK1, WNT1, DCK | MTOR 403/4885RPTOR 2148/4885MLST8 3030/4885 |
| US-20170027932-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | MTOR, TTK, RICTOR | MTOR 1/4885RPTOR 6/4885MLST8 93/4885 |
| US-20120028972-A1 | BIOMARKER ASSAYS FOR DETECTING OR MEASURING INHIBITION OF TOR KINASE ACTIVITY | MTOR, RPTOR, ULK1 | MTOR 1/4885RPTOR 2/4885MLST8 35/4885 |
| US-20100216781-A1 | mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY | MTOR, RICTOR, RPTOR | MTOR 1/4885RPTOR 3/4885MLST8 33/4885 |
| US-20110137028-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885RPTOR 478/4885MLST8 2577/4885 |
| US-20130245254-A1 | METHODS OF SYNTHESIS AND PURIFICATION OF HETEROARYL COMPOUNDS | AGER, GPR119, REL | MTOR 595/4885RPTOR 478/4885MLST8 2577/4885 |
| US-20150174128-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MTOR 3624/4885RPTOR 3916/4885MLST8 1475/4885 |
| US-20170095475-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MTOR 3624/4885RPTOR 3916/4885MLST8 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.